D rug-eluting stents (DESs) have reduced the rate of instent restenosis in comparison with bare-metal stents.
The underlying plaque morphology is an important substrate for vascular healing after DES implantation, and culprit lesions in patients treated with DES implantation because of myocardial infarction (MI) are associated with substantial delay in arterial healing in comparison with DES treatment of patients with stable coronary artery disease. 5, 6 Besides clinical indication and underlying plaque morphology, sufficient and potent strut coverage depends on several additional factors, among other patient characteristics, stent type, and numerous procedural factors. 7 Particularly, acute incomplete stent apposition (ISA) is a strong procedural risk factor for later deficient neointimal coverage. 8, 9 Optical coherence tomography (OCT) is a high-resolution intravascular imaging modality that enables in vivo evaluation of the immediate stenting result and the vascular healing pattern including strut coverage at follow-up. 4, 10, 11 Some procedural factors can be modified using OCT guidance, including strut apposition and stent expansion, potentially leading to a decrease in the proportion of uncovered struts at follow-up.
The objective of this study is to investigate whether OCTguided optimization after Nobori biolimus-eluting stent (N-BES) implantation in patients with non-ST-segment elevation MI (NSTEMI) provides improved stent strut coverage at 6 months in comparison with routine angiographic guidance only.
Methods

Study Design and Patient Population
This study was designed as a prospective, randomized trial conducted at a single center (Odense University Hospital, Odense, Denmark). Patients were enrolled between August 2011 and May 2013. Patients were eligible for participation in the trial if they were (1) ≥18 and <80 years of age, (2) a NSTEMI had been diagnosed, 12 (3) a de novo culprit lesion (≥50% diameter stenosis) in the coronary arteries had been visually identified on coronary angiography, and (4) percutaneous coronary intervention (PCI) with stent implantation was indicated. Exclusion criteria comprised (1) left main disease, (2) extremely
WHAT IS KNOWN
• The risk of late-and very late stent thrombosis is a major safety concern after percutaneous coronary intervention with drug-eluting stent implantation.
• In previous histopathologic studies, incomplete endothelial strut coverage has been associated with late thrombotic events.
• By modifying procedural factors, optical coherence tomography guidance has the potential to decrease the proportion of uncovered struts at follow-up and improve outcomes.
WHAT THE STUDY ADDS
• Optical coherence tomography-guided percutaneous coronary intervention significantly lowers percentage of uncovered struts at 6-month follow-up compared with routine angiographic guidance only, and complete stent strut coverage is significantly more prevalent after optical coherence tomography-guided drug-eluting stent implantation. (7) plasma creatinine >170 µmol/L. Before the procedure, patients were loaded with a 300-mg dose of aspirin and a 180-mg loading dose of ticagrelor.
The study was approved by the institutional review committee (Ethical Committee project ID: S-20110030, Danish Data Agency project ID: 2011-41-6020), and written informed consent was obtained from all patients.
Percutaneous Coronary Intervention
An unfractionated heparin dose (70 IU/kg) was administered before the PCI-procedure. In all cases, the third-generation biolimus-eluting biodegradable-polymer stent (Nobori; Terumo, Tokyo, Japan) was implanted. Stents were implanted according to standard techniques. The culprit lesion was identified by the PCI operator based on a combination of electrocardiographic findings (if any), possible left ventricular wall motion abnormalities on echocardiography, and lesion morphology on angiography. The interventionalists visually estimated angiographic variables, and direct stenting without prior balloon dilation was allowed. Recommended postprocedure dual antiplatelet regimens were 75-mg aspirin daily lifelong and 90-mg ticagrelor twice daily for 1 year.
Randomization and Implantation Techniques
Post stenting, after obtaining an angiographic optimal result, eligible patients for this study were randomly assigned to either (1) OCTguided PCI or (2) angio-guided PCI. Random assignments to the treatment groups were distributed in sealed envelopes. Patients randomized to angio-guided PCI had a documentary OCT after completion of the intervention. It was not possible to blind the operator, investigator, or patient for the allocated implantation technique, but the operator was blinded to the postprocedure OCT images, because the operator screen-side was turned off, and the entire pullback remained uncommented on. In the OCT-guided group, the postprocedure OCT images were interpreted online by a dedicated OCT analyst and the PCI operator. The OCT criteria used to describe suboptimal stent implantation were partly adapted from the Multicenter Ultrasound Stenting in Coronaries (MUSIC) criteria 13 and consisted of the following: (A) significant stent underexpansion (defined as minimal stent area <90% of the distal/proximal reference vessel lumen area); (B) significant malapposition (defined as ≥3 struts per cross-sectional area detached >140 µm from the underlying vessel wall); (C) significant edge dissection (causing a minimal lumen area <4 mm 2 ), and (D) significant residual stenosis (causing a minimal lumen area, <4 mm 2 ; Figure 1 ). If OCT criteria of suboptimal stent deployment were met, and if considered safe and feasible, additional in-stent postdilation or supplementary stenting was performed. The degree of optimization based on image findings was left to the judgment of the operator. In patients with (A) and (B), the operator was encouraged to postdilate, and in patients with (C) and (D), the operator was encouraged to implant an additional stent at the edge(s) of the previously implanted stent.
OCT Imaging and Analysis
OCT imaging of the target lesion was performed both post procedure and at 6-month follow-up using a frequency-domain OCT system (C7-XR or Ilumien OCT system; LightLab Imaging, Inc, St. Jude Medical, Figure 2 . Flowchart of enrolled patients. In the 9 OCT-guided patients lost to follow-up, 3 of them had further intervention at baseline, whereas the remaining 6 patients had no further dilation or stent implantation performed. OCT indicates optical coherence tomography; and PCI, percutaneous coronary intervention. *OCT system failure occurred in 2 OCT-guided cases, and intravascular ultrasound guidance was performed instead. OCT Guidance and Stent Strut Coverage St. Paul, MN). After administration of 200-µg intracoronary nitroglycerin (and a weight-adjusted unfractionated heparin dose in follow-up procedures), the imaging was performed. A 2.7F C7 Dragonfly Imaging Catheter (LightLab Imaging, Inc), flushed with 20-mL undiluted contrast was used. Motorized pullback OCT imaging was performed at a pullback rate of 20 mm/s throughout the stent. The system was calibrated to the reflection of the imaging wire; then, images, areas, and distances of interest were carefully interpreted in the OCT-guided group.
Quantitative OCT analysis was performed using the OCT proprietary software (Offline Review Workstation; LightLab Imaging, Inc) by an experienced OCT analyst. The OCT analyst was blinded to the implantation technique, when analyzing 6-month pullbacks. Lesions were analyzed at the cross-sectional level with an interval of 1 mm (every 5 frames). Paired analysis was limited to those patients who had OCT at both baseline and 6-month follow-up.
Stent and luminal areas were measured in all cross-sectional areas, and the stent volumes and luminal volumes were calculated. Neointimal hyperplasia volume was calculated as the stent volume minus the luminal volume.
Strut coverage was assessed using the following healing subtypes: (1) definitely uncovered, (2) uncovered/fibrin, (3) partially uncovered, (4) covered protruding, (5) covered embedded, and (6) covered proliferative. Subtypes 1, 2, and 3 accounted for the proportion of uncovered struts, whereas subtypes 4, 5, and 6 accounted for the proportion of covered struts. Subtypes 1, 2, and 3 were defined as having a neointimal hyperplasia thickness of 0 μm. In subtypes 4, 5, and 6, strut coverage was measured as the distance between the endoluminal side of the strut from the midpoint of its long axis and the intersection of the lumen contour with a straight line between the endoluminal side of the strut and the gravitational center of the vessel. 11, 14 Apposition was assessed by measuring the distance between the center of the endoluminal surface of the strut and the intersection between the lumen contour and the line connecting the center of the endoluminal strut side and the gravitational center of the vessel. 14, 15 A malapposed strut was defined as a strut that had detached >140 µm (thickness of strut, 120 µm; antiproliferative drug and polymer, 20 µm) 16 from the underlying vessel wall. The percentages of malapposed or uncovered struts were calculated as the number of malapposed or uncovered struts/total number of struts in all cross sections of the lesion×100, respectively. For the evaluation of the magnitude of malapposition, malapposition areas, malapposition distances, and malapposition volumes were measured/calculated.
Both cross-sectional areas containing stent overlap and side branches were included in the analysis. Struts located at the ostium of side branches were excluded from the analysis of apposition.
Baseline and follow-up subclinical intrastent thrombi were defined as irregular masses protruding into the lumen (see Methods section in the Data Supplement).
End Points
The primary end point of the study was the difference in percentage of uncovered struts in the OCT-guided versus the angio-guided group at 6-month follow-up.
Secondary end points were differences between treatment groups in (1) percentage of acutely malapposed struts at baseline, (2) percentage of malapposed struts at 6-month follow-up, and (3) percentage of struts being both malapposed and uncovered at 6-month follow-up.
Statistical Analysis
An a priori power calculation at the patient level with a mean expected proportion of 66% and 90% covered struts at 6 months in the angio-guided and OCT-guided group, respectively, showed that a sample size of 86 patients (n=43 in both treatment groups) was required to reach statistical significance. With 43 patients in each treatment group, and a 2-tailed significance level of 0.05, the study would have a power of 80%. With an expected drop-out rate of 14% because of noncompliance in relation to the requisite invasive procedures, and subject to poor image quality, 100 patients were required recruited. Categorical data are presented as numbers and frequencies, and compared with χ 2 or Fisher exact statistics. Continuous data are presented as the mean±SD and compared with the Values are expressed as mean±SD or median (interquartile range), depending on whether data followed the normal distribution, and n (%) for categorical data. CABG indicates coronary artery bypass grafting; IHD, ischemic heart disease; MI, myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; and TIMI, thrombolysis in myocardial infarction (grading scale for coronary blood flow).
*Multiple lesions: ≥2 lesions with >50% diameter stenosis. †Multiple lesions PCI treated: ≥2 lesions treated with stent implantations. OCT Guidance and Stent Strut Coverage Values are presented as n, mean±SD, median (interquartile range), or n (%). OCT indicates optical coherence tomography; and PCI, percutaneous coronary intervention. *Because of OCT system failure in 2 OCT-guided cases, intravascular ultrasound guidance was performed instead. OCT Guidance and Stent Strut Coverage Student t test. If the distributions were skewed, a nonparametric test was performed, and the median with an interquartile range is provided.
The statistical analysis of strut coverage and apposition was performed on the patient/lesion level.
The primary and secondary end points were assessed by the Kruskal-Wallis test, the Wilcoxon rank-sum test, and an ordered logistic regression analysis, where randomization group was set as a fixed effect and adjusted for covariates (lesion length, number of struts, stents per patient, and time to follow-up).
The randomness inherent in the number of struts for each individual patient was taken into account by performing a supplementary generalized linear mixed model analysis, where the variable number of struts was set as a random effect, and randomization group was set as a fixed effect.
An interobserver reliability analysis using the Kappa (κ) statistics was performed for 10% randomly selected postprocedure and corresponding 6-month follow-up pullbacks to determine consistency on strut apposition and coverage between 2 dedicated OCT analysts. All tests were 2 tailed, and a value P<0.05 was considered statistically significant. SPSS version 22.0 (SPSS Inc, Chicago, IL) was used for the statistical analysis.
Results
A flowchart of enrolled patients is provided in Figure 2 . In total, n=100 patients were enrolled in the study. One OCTguided patient was excluded periprocedurally because of stenting-induced culprit vessel dissection and hemodynamic instability. OCT system failure occurred in 2 OCT-guided cases and intravascular ultrasound guidance was performed instead.
In total, 23 (46%) OCT-guided patients had further postdilation or stenting after intravascular guidance. Four (17.4%) patients indicated additional stent implantation because of an edge dissection causing significant lumen reduction, 10 (43.5%) patients had supplementary postdilation because Representative healing examples from the angio-guided group. A1, Acute incomplete stent apposition (ISA) caused by stent underexpansion. A2, Impaired healing. Some struts are protruding, others are partially uncovered, and some are persistently malapposed. B1, There is noticeable intrastent plaque rupture at 2 sites (arrows). B2, There has been competent healing; however, some struts remain partially uncovered. C1, Stent underexpansion and acute ISA at a lipid-rich plaque-rupture site (arrow). C2, Heterogeneous healing, as previously malapposed struts from 7 o'clock to 9 o'clock are partially uncovered. OCT Guidance and Stent Strut Coverage of significant acute ISA, 8 (34.8%) patients required further postdilation because of stent underexpansion, and 1 (4.3%) patient had additional stenting because of a significant residual stenosis.
Nine patients from the OCT-guided group were lost to invasive follow-up (n=7 patients declined, n=1 patient was excluded as it was impossible to flush the vessel sufficiently at follow-up, and n=1 patient was excluded because of development of severe cognitive deficits). Five patients from the angio-guided group were lost to invasive followup (n=3 patients declined, n=1 patient developed a subacute stent thrombosis, and n=1 patient suffered a cardiac death). Accordingly, both postprocedure and 6-month OCT data were available in 38 (76.0%) patients from the OCTguided group (n=2 OCT-guided [4%] patients had postprocedure intravascular ultrasound guidance and 6-month OCT evaluation) and in 45 (90%) patients from the angioguided group.
Clinical and Procedural Characteristics
Baseline clinical and procedural characteristics are listed in Table 1 . The treatment groups were well balanced without any significant differences in baseline characteristics. Also, there were no significant differences in baseline characteristics between patients with versus patients without scheduled 6-month OCT-control. Maximum balloon pressures were substantially higher, significantly more contrast was used, and both flouro-and procedure times were considerably longer in the OCT-guided group.
Optical Coherence Tomography
Postprocedure and 6-month follow-up OCT findings are presented in Table 2 . In total, n=3944 cross-sectional areas and n=40 012 struts were analyzed.
Stent Strut Coverage
The interobserver reliability for the qualitative determination of strut coverage at 6-month follow-up was found to be κ=0.88 (95% confidence interval [CI], 0.85-0.91; P<0.01).
At 6-month follow-up, the percentage of uncovered struts was significantly lower in the OCT-guided group (4 Illustrative examples of healing patterns for the 2 treatment groups are provided in Figures 3 and 4 . The percentage of struts being both uncovered and malapposed at 6-month follow-up did not differ between groups.
Two patients (n=1 OCT guided and n=1 angio guided) had in-stent neoatherosclerotic changes in form of inflammatory and lipid-laden neointima, causing asymptomatic in-stent restenosis at follow-up ( Figure 5 ). 
OCT Guidance and Stent Strut Coverage
The incidence of subclinical intrastent thrombi did not differ significantly between OCT-guided and angio-guided patients at follow-up: n=0 (0.0%) versus n=3 (6.7%), P=0.24. All subclinical thrombi were in relation to uncovered and malapposed struts.
Dynamic Malapposition Findings
The interobserver reliability for the qualitative determination of strut malapposition was found to be κ=0.73 (95% CI, 0.60-0.85; P<0.01).
There was no significant difference in incidence of acute ISA (≥1 ISA strut(s)) between OCT-guided and angio-guided patients: 76.3% versus 86.7%, P=0.22. However, the postprocedure total malapposition area and the postprocedure total malapposition volume were significantly smaller in the OCTguided group ( At 6-month follow-up, the percentage of malapposed struts was comparative between OCT-guided and angioguided patients. Moreover, the course of ISA was comparable between OCT-and angio-guided patients (P=0.29), as 40.0% versus 53.3% had resolved ISA, 30.0% versus 33.3% had persistent ISA, and 7.5% versus 2.2% had late acquired ISA. Representative examples of the ISA subtypes are presented in Figure 6 . At receiver operating characteristics curve analysis, an acute maximal malapposition distance of ≤335 μm was the best cutoff value for resolved ISA at follow-up (area under the curve, 0.79; 95% CI, 0.68-0.89; P<0.01).
Clinical Outcome
During the 6-month follow-up, 2 (4%) patients from the angioguided group had a major adverse cardiac event (n=1 subacute stent thrombosis 1.5 days post implantation and n=1 cardiac death [autopsy-confirmed ventricular rupture] 6 days post implantation). No cardiac events were registered in the OCTguided group during follow-up. The clinical course of the patients who declined further invasive follow-up was uneventful.
Discussion
This is the first randomized trial to investigate the impact of OCT-guided optimization after N-BES-implantation in patients with NSTEMI on strut coverage at 6-month in comparison with angiographic guidance alone.
The main findings of our study are as follows: (1) OCTguided PCI improved midterm healing, as it provided a significantly lower percentage of uncovered struts at 6-month follow-up compared to angiographic guidance only; (2) complete strut coverage was significantly more prevalent in the OCT-guided group; (3) OCT optimization significantly reduced the percentage of acutely malapposed struts, the postprocedure total malapposition area, and malapposition volume, and (4) in the majority of both OCT-and angio-guided patients, the acute ISA had resolved at 6-month follow-up.
Studies investigating potential vessel wall healing benefits of OCT-guided PCI are lacking. The issue is of great clinical importance because the potential of achieving better and faster neointimal coverage may reduce the period of thrombotic risk after stent implantation and shorten the duration of dual antiplatelet therapy. This study demonstrates that OCT-guided PCI, based on well-defined criteria, reduces the proportion of acutely malapposed struts and leads to a faster and more complete strut coverage in N-BES-treated NSTEMI patients. In spite of the high-risk study population with complex and thrombotic lesions investigated, the implantation technique improved the midterm vascular healing. Notably, OCT-guided patients had substantially more segments with stent overlap, and also OCT-guided lesions tended to be slightly more thrombotic. These lesion-related features have previously been found to predispose for insufficient arterial healing, 5, 6, 17 but did not affect the strut coverage adversely in the present study.
OCT is a promising imaging modality in guiding PCI procedures 18, 19 because the technique facilitates the visualization of the lumen and depicts superficial vessel wall structures with high accuracy. 19 However, there is a paucity of data on OCT criteria for optimization of stent implantation.
It is a challenging task to define which OCT-detected angiographically silent features that warrants further intervention.
18,20
Figure 5. Example of in-stent neoatherosclerotic changes observed at follow-up. Left, There is an eccentric fibro-fatty plaque from 11 o'clock to 3 o'clock and acute incomplete stent apposition from 3 o'clock to 8 o'clock, where the underlying vessel wall has a normal 3-layered structure. Right, The neointima is heterogeneous in appearance, and around 10 o'clock, the coverage is signal poor, immature, and lipid-laden. White arrows point out peristrut macrophages, an area with peristrut low intensity and a site with ruptured neointima.
OCT Guidance and Stent Strut Coverage
The quantitative OCT criteria for suboptimal stent deployment in the present study were partly based on thresholds previously defined by intravascular ultrasound. 13 Furthermore, criteria were based on intrastent features that previously had been associated with delayed arterial healing, 8 and an increased risk of later major adverse cardiac events. 21, 22 In approximately one half of the OCT-guided patients, the detailed stent evaluation changed the operator's strategy and resulted in additional intervention. This reintervention rate is comparable with findings from a limited number of previous studies [23] [24] [25] that have used comparable OCT criteria for stent optimization and found indication for additional intervention in 32% to 60% of their OCT-guided cases. However, the functional and clinical results of such OCT-driven decision making remain to be illuminated.
A severely diseased underlying vessel wall often causes acute ISA, ie, a seriously calcified lesion might not allow homogeneous stent expansion. Other underlying pathologies, such as jailed thrombus and plaque ruptures, may also preclude sufficient stent deployment. 8, 9, 26 A high incidence of acute ISA was found in the present study. Even in the OCTguided group, where approximately one half of the patients had reintervention performed, and predominately in form of postdilation because of significant malapposition in the initial OCT evaluation. Nevertheless, the number of malapposed struts, the total malappostion area, and malappostion volume postprocedurally were significantly lowered by OCT guidance. Our results imply that it is possible to reduce the magnitude of acute ISA by performing OCT-driven postdilation. However, culprit lesions from patients with MI are severely diseased coronary vessel wall sites more prone to suboptimal apposition, 4, 5 probably explanatory to our acute ISA findings. In previous OCT studies, 8, 9, 27, 28 coverage of ISA struts has been found to be delayed when compared with well-apposed Figure 6 . Representative examples of different incomplete stent apposition (ISA) subtypes. A1, Widespread acute ISA. A2, Resolved ISA at follow-up. B1, Four struts are acutely malapposed. B2, One strut is persistently malapposed (arrow), and there is a large malapposition area (MA). C1, All struts are well apposed with underlying jailed thrombus. C2, Thrombus resolution has resulted in late acquired ISA. An organized thrombus (arrow) is adherent to the MA. OCT Guidance and Stent Strut Coverage struts in DES. Gutiérrez-Chico et al 8 found a 9× higher risk of incomplete coverage for ISA struts versus well-apposed struts. Our results are in line with these previous findings, as the improved strut coverage observed at 6-month follow-up in the OCT-guided group is interpreted caused by the better apposition of the stents at baseline. Taken together, previous findings and current observations suggest that acutely malapposed struts are a primary risk factor for delayed strut coverage, justifying the effort to optimize apposition to improve the subsequent healing.
In total, 47% of the study cohort had resolved ISA at 6-month follow-up. Despite a major risk of struts being in contact with underlying necrotic core and other acellular material in such a MI population, 4,5 the majority of our cohort exhibited a significant vascular regeneration potential. Previously, Gutiérrez-Chico et al 29 also investigated the coronary healing of acute ISA by doing sequential OCT assessment, and found that 71.5% of the ISA segments were completely integrated into the vessel wall at 6 months. They demonstrated that all ISA sites with an acute maximal ISA distance <270 μm were reapposed at follow-up. In concordance with their findings, we found that lesions with an acute maximal ISA distance of ≤335 μm were resolved at followup. Still, increasing ISA detachment causes increasingly heterogeneous and incomplete neointimal coverage. Foin et al 27 recently found that flow disturbances and risk of delayed strut coverage both increased with increasing ISA detachment distances. The question of what degree of acute ISA that is clinically worth to correct is still largely undetermined. Only a small proportion of our cohort developed subsequent late acquired ISA at 6-month follow-up. In all cases, dissolution of initially jailed thrombus was the cause. In accordance with previous findings by Ozaki et al, 9 this seemed a quantitatively less important mechanism of ISA at follow-up than persistence of acute ISA.
Inexplicably, subclinical thrombi were only observed in relation to late, uncovered ISA struts in the angio-guided group. This finding may be a play of chance.
Previously, several OCT studies 11, 15, 28 have evaluated the healing capabilities of BES (N-BES and Biomatrix) at different time points. The majority of these studies have concluded that BESs promote faster initial healing than older generation DESs. Our findings emphasize that the beneficial N-BES healing potential can be extrapolated to a patient population exclusively treated because of NSTEMI.
Recently, in-stent neoatherosclerotic has been identified as an important predisposing factor for later thrombotic events.
3,30 Two of our cases had in-stent neoatherosclerotic changes at follow-up causing asymptomatic in-stent restenosis. In one case, the underlying vessel wall was characterized by intrastent plaque disruption at baseline, and in the other case there was an eccentric fibro-fatty plaque and severe malapposition at the later neoatherosclerotic site. The underlying processes responsible for the development of neoatherosclerosis are thought to be multifactorial, but the inability of a severely diseased vessel wall to maintain a fully functional endothelialized luminal surface within the stented segment is believed to play a key role. 3, 30 In spite of the limited number of cases, our observations support these assumptions.
To date, few previous studies have attempted to clarify the clinical benefits of OCT guidance, but the interpretation of their results has been limited by small sample sizes, 24 and nonrandomized study designs. 23, 25 Recently, an observational study by Prati et al 25 suggested improved clinical outcome in patients undergoing OCT-guided PCI. Large prospective, randomized, serial OCT studies combined with long-term clinical follow-up are warranted to conclude the clinical benefits of OCT-guided stent implantation. In addition, it is necessary to clarify whether the currently observed vessel wall healing benefits offsets potential procedural cons induced by an OCTguided implantation strategy, such as longer stented segments, longer procedures (ie, radiation exposure), and more use of contrast.
Limitations
First, this study was designed as an open-label randomized trial. Second, the sample size was relatively small. Only patients indicating PCI because of NSTEMI were enrolled, and only N-BES were implanted. Therefore, results may be difficult to generalize or to apply to less selected patients in different clinical settings. Third, the presence or absence of strut coverage is limited by the resolution of OCT, and struts interpreted as exposed could have a thin layer of tissue coverage (<10-15 µm). However, the thrombotic protectiveness of such a thin layer is questionable. 4 Also, the current OCT technology has limitations in separating fibrin and thrombus from healthy neointima. The time point of OCT assessment was empirical, and imaging at longer follow-up periods may provide additional relevant information.
Conclusions
OCT-guided optimization of N-BES implantation improves stent strut coverage at 6-month follow-up in patients having PCI because of NSTEMI by providing better immediate stent strut apposition in comparison with angiographic guidance alone.
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